LONDON - Antisoma plc reported further clinical progress with its first-in-class vascular disrupting agent ASA404, announcing two-year survival of 33 percent in hormone refractory prostate cancer patients receiving ASA404 plus docetaxel, vs. 23 percent in the control group, which received docetaxel alone. (BioWorld International) Read More
